Equivalent price position
Unlock the full competitive price benchmark
See the exact peer median, min/max and quartiles, product rank, price percentile and the complete like-for-like competitor table.
Price-position comparison uses current official listed prices normalized to compatible units. It is a price benchmark, not a measure of sales, demand, prescription volume or market share.
Product details
- Generic
- Empagliflozin + Metformin
- Therapeutic area
- Endocrine & metabolic
- Drug class
- Antidiabetic medicines
- ATC
- A10BA
- Strength
- 25 mg + 1000 mg
- Dosage form
- Extended-release tablet
- Pack
- 14's
- Registration no.
- 120004
- Price record verified
- 2026-08-08
- Latest DRAP source check
- 2026-11-13 03:02
Manufacturer
Explore this manufacturer's complete MedInfoBase portfolio, generics and current listed prices.
View company portfolio →What Empator-M (Empagliflozin with metformin) is used for
This is a prescription tablet for type 2 diabetes that contains two diabetes medicines in one. Empagliflozin is an SGLT2 inhibitor: it helps the kidneys get rid of extra sugar in the urine. Metformin mainly cuts down the amount of sugar the liver makes. Together they lower blood sugar. It is used alongside a healthy diet and exercise, and it can replace taking empagliflozin and metformin as two separate tablets.
- Type 2 diabetes in adults, when metformin on its own does not control blood sugar well enough
- Type 2 diabetes alongside other diabetes medicines, including insulin, when they are not controlling blood sugar well enough
- People who already take empagliflozin and metformin as separate tablets and want to switch to one combined tablet
- The Irish product leaflet also allows use in children aged 10 and over with type 2 diabetes; a doctor decides if it is suitable
Get medical help straight away if
- Get emergency help for signs of lactic acidosis (a rare, dangerous build-up of acid): being sick, stomach pain, muscle cramps, feeling very weak or tired, trouble breathing or fast deep breathing, feeling very cold, or a slow or fast heartbeat. Stop the tablets and get help straight away.
- Get urgent help for signs of diabetic ketoacidosis (DKA): feeling or being sick, very strong thirst, stomach pain, fast or deep breathing, confusion, unusual sleepiness, quick weight loss, or breath that smells sweet or fruity. This can happen even when blood sugar is normal. Stop the tablets and contact a doctor urgently.
- Get urgent help for severe pain, tenderness, redness or swelling of the genitals or the area between the genitals and the bottom, with a fever or feeling unwell. This can be a rare, serious infection (Fournier's gangrene).
- Call an ambulance for a severe allergic reaction: swelling of the face, lips, tongue or throat, or difficulty breathing or swallowing.
Side effects, warnings and interactions for Empagliflozin with metformin
Prepared from the sources listed by the MedInfoBase team. General information, not medical advice: it gives no doses. Your doctor or pharmacist decides the medicine and dose for you.
Our condition guides that mention Empagliflozin + Metformin
From our condition guides, written from WHO, NICE and other opened sources. Your doctor decides if Empagliflozin + Metformin is right for you and the dose.
- Type 2 diabetes mellitus: given with metformin as first-line treatment for most adults
About Empator-M 25 mg + 1000 mg extended-release tablet
Empator-M 25 mg + 1000 mg extended-release tablet contains Empagliflozin + Metformin 25 mg + 1000 mg. It is registered with DRAP by Martin Dow Limited (registration no. 120004). Its official price is PKR 996.72 for a pack of 14's, about PKR 71.19 per tablet. This price has applied since 22 July 2026. Empator-M is also available as 10 mg + 1000 mg extended-release tablet, 12.5 mg + 1000 mg extended-release tablet, 5 mg + 1000 mg extended-release tablet and 12.5 mg + 1000 mg tablet. 2 other brands of Empagliflozin + Metformin 25 mg + 1000 mg (extended-release tablet) are registered in Pakistan. Compare all brands and prices →
Other strengths of Empator-M
All 2 other brands of Empagliflozin + Metformin 25 mg + 1000 mg tablet in Pakistan
These 2 brands are alternatives (substitutes) to Empator-M: each contains Empagliflozin + Metformin 25 mg + 1000 mg tablet. Ask your doctor or pharmacist before you switch brands.
Sorted by price per tablet, lowest first. The lowest is Diampa-M XR (Getz Pharma (Pvt) Limited) at PKR 59.80 per tablet; the highest is Empaphage-M at PKR 63.14. All prices are official DRAP prices.
| Brand | Company | Pack | Official price | Per unit |
|---|---|---|---|---|
| Diampa-M XR | Getz Pharma (Pvt) Limited | 14's | PKR 837.18 | PKR 59.80 / tablet |
| Empaphage-M | Martin Dow Marker Limited | 14's | PKR 883.93 | PKR 63.14 / tablet |
Where to buy
MedInfoBase does not sell medicines and takes no orders. The company below holds the DRAP registration for Empator-M, so it is the right place for a pharmacy, distributor or hospital buyer to ask about supply. A patient should buy from a licensed pharmacy.
- Registration holder
- Martin Dow Limited, Karachi
- DRAP registration
- 120004
- Phone
- +92 21 111 111 634
- info@martindow.com
- Website
- https://www.martindowltd.com/
- Contact page
- Company contact page
Contact details as published by the company, last checked on 16 August 2026 (not yet independently verified). The price on this page is the official DRAP maximum retail price: a pharmacy may charge that or less, never more.
Official price over time
No change in the official DRAP price is recorded for this pack (14's). Current price PKR 996.72, effective 22 Jul 2026.
Cite this price history
MedInfoBase. Empator-M 25 mg + 1000 mg, 14's: official price history (source: DRAP PharmaPrice Index). https://medinfobase.com/brand/empator-m-25-mg-1000-mg-120004-14s-martin-dow-limited/ (accessed 13 November 2026).
Official price history
| Amount | Effective from | Verified | Source | Status |
|---|---|---|---|---|
| PKR 996.72 | 2026-07-22 | 2026-08-08 | DRAP PharmaPrice Index | Current |
Cite this record
Medicine record · DRAP registration 120004Price and registration data on this page were observed on 8 August 2026. Records change over time, so please cite the observation date alongside the access date.